GLP-1 Agonists in Type 1 Diabetes: Incretin Adjunct Therapy Review

SNIPPET: GLP-1 receptor agonists used as adjunct therapy in type 1 diabetes reduce HbA1c by 0.23%, body weight by 3.93 kg, and total daily insulin dose by 5.74 U/day without increasing severe hypoglycemia risk, according to meta-analyses of 25 RCTs. Meanwhile, emerging triple-receptor agonists targeting GLP-1, GIP, and glucagon receptors reveal a GLP-1-receptor-centric mechanism via the Gαq–TRPM5 signalling pathway, reshaping how we understand incretin pharmacology.

THE PROTOHUMAN PERSPECTIVE#

For decades, type 1 diabetes has been treated as a single-tool problem: insulin in, glucose managed, end of story. Except it isn't the end. Only about 20% of people with T1D achieve adequate glycemic control, and the obesity epidemic hasn't spared this population — compounding insulin resistance on top of autoimmune β-cell destruction. That's a metabolic double bind that insulin alone was never designed to solve.

What's shifting now is the recognition that incretin-based therapies — originally built for T2D — may have a legitimate role in T1D management. Not as replacements for insulin, but as adjuncts that address the metabolic dimensions insulin can't touch: appetite regulation, weight management, and possibly even residual β-cell preservation. The emergence of dual and triple-receptor agonists adds another layer. If the GLP-1 receptor is doing the heavy lifting even in multi-agonist compounds, as preclinical data now suggests, the therapeutic architecture of these drugs needs rethinking. This matters for anyone optimizing metabolic health — diabetic or not — because these pathways govern glucose disposal, satiety signalling, and energy partitioning at a fundamental level.

THE SCIENCE#

Incretins Beyond Type 2: Why GLP-1 RAs Deserve a Second Look in T1D#

GLP-1 receptor agonists — semaglutide, liraglutide, exenatide — were developed for type 2 diabetes, where insulin resistance and declining β-cell function are the primary drivers. Type 1 diabetes is a different animal: autoimmune-mediated β-cell destruction, typically resulting in near-total insulin dependence. So why would a drug class designed to enhance endogenous insulin secretion matter here?

The answer lies in what GLP-1 RAs do beyond insulin secretion. They suppress glucagon (which is dysregulated in T1D, not just T2D), slow gastric emptying, reduce appetite centrally, and — this is the part that gets insufficiently discussed — may exert protective effects on residual β-cell mass. Adult-onset T1D, in particular, often retains more residual endogenous insulin secretion than childhood-onset disease, making it a distinct therapeutic target ^[5].

Popovic et al. (2025) in Nature Reviews Endocrinology argue that adult-onset T1D differs meaningfully from the early-onset form in comorbidity burden and baseline cardiorenal risk, and that GLP-1 RAs could serve a dual purpose: preserving whatever β-cell function remains while mitigating cardiovascular risk that accumulates over decades of disease ^[5].

The Meta-Analytic Evidence: Modest but Real#

Two independent meta-analyses published in 2025 give us the clearest picture yet of GLP-1 RA efficacy in T1D.

The larger of the two, published in Hormones by a team including Popovic, Koufakis, and Patoulias, pooled 25 RCTs and found that adding a GLP-1 RA to insulin reduced HbA1c by 0.23% (95% CI: −0.30 to −0.17), body weight by 3.93 kg (95% CI: −4.29 to −3.56), and total daily insulin dose by 5.74 U/day (95% CI: −7.30 to −4.19) ^[4]. Critically, severe hypoglycemia risk was not increased — a concern that has historically blocked off-label use.

Mirghani and Alhowiti's meta-analysis in Frontiers in Endocrinology, drawing on 10 trials, found convergent results: HbA1c reduction with an SMD of 0.23 (Z = 5.27), and a dose-response relationship where liraglutide 1.2 mg and 1.8 mg outperformed 0.6 mg ^[3].

Let me be direct about what these numbers mean. A 0.23% HbA1c reduction is clinically modest. In T2D trials, we see 1–1.5% drops. But in a population where achieving any reduction has proved stubbornly difficult, and where the intervention also shaves off nearly 4 kg and reduces insulin requirements, the combined value proposition is more compelling than any single number suggests.

The catch, though. Time-in-range — arguably the metric that matters most for day-to-day glycemic quality — was not significantly improved ^[4]. That's a gap I'd want closed before endorsing widespread adoption.

The Triagonist Frontier: IUB447 and the Gαq–TRPM5 Revelation#

While the T1D adjunct story is playing out in clinical meta-analyses, a parallel line of research is unpacking how multi-receptor agonists actually work at the cellular level — and the answer is not what the marketing suggests.

IUB447 is a unimolecular triagonist targeting GLP-1, GIP, and glucagon receptors simultaneously. In a 2025 study published in Diabetologia, researchers used a series of knockout mouse models to dissect which receptor was actually driving insulin secretion enhancement ^[2].

The results were striking. The triagonist enhanced glucose-stimulated insulin secretion (GSIS) to a greater degree than co-administration of individual mono-agonists — confirming that unimolecular design has pharmacological advantages beyond convenience. But here's where it gets interesting: knocking out either the GIP receptor or the glucagon receptor alone didn't blunt the triagonist's effect. It was only when both GLP-1R and GIPR were knocked out, or when the GLP-1R-specific antagonist exendin-3(9–39) was applied, that the insulin secretion boost disappeared ^[2].

The downstream pathway? Gαq signalling through TRPM5 (transient receptor potential melastatin 5). Blocking Gαq with YM254890 or TRPM5 with triphenylphosphine oxide abolished the triagonist's GSIS enhancement. In high-fat-fed TRPM5-knockout mice, the triagonist failed to improve glycemic management entirely ^[2].

The implication is clear: even in a "triple agonist," the GLP-1 receptor is doing the heavy pharmacological lifting for insulin secretion, with the Gαq–TRPM5 axis as the critical amplification pathway. The GIP and glucagon receptor components may contribute to other outcomes — appetite, energy expenditure, lipid metabolism — but the core insulinotropic effect is GLP-1R-centric.

I'm less convinced that this means GIP is irrelevant. Almorza-Gomar et al. (2026) emphasize GIP's complex pleiotropic profile — including its actions on adipose tissue and its dual modulation of both insulin and glucagon — which may manifest over longer treatment durations and in metabolic endpoints beyond acute insulin secretion ^[1]. But for anyone claiming triple agonists are a quantum leap because they hit three receptors, this data demands more nuance.

GIP: The Misunderstood Incretin#

GIP's pharmacology is genuinely confusing, and the field hasn't helped by calling it "dual-acting" without specifying what that means. As the Almorza-Gomar review clarifies, GIP's duality can refer to either its capacity to regulate both insulin and glucagon secretion, or to its distinct central versus peripheral actions ^[1]. These are not the same thing, and conflating them has muddied drug development strategies.

The rationale for combined GIP/GLP-1 analogues like tirzepatide — and for triple agonists like retratutide (LY3437943) that add glucagon receptor engagement — was built on the premise that GIP contributes meaningfully to glycemic and weight outcomes. Tirzepatide's clinical success supports this at the outcomes level. But the IUB447 mechanistic data suggests we need to be more precise about which outcomes each receptor component is driving.

COMPARISON TABLE#

THE PROTOCOL#

For individuals with T1D considering GLP-1 RA adjunct therapy — this is not a self-prescribe situation. The protocol below is based on current evidence and should be implemented under endocrinologist supervision.

1. Establish baseline metrics. Before initiating any GLP-1 RA, document your current HbA1c, total daily insulin dose (TDI), body weight, and ideally run a 14-day CGM report for time-in-range, time-below-range, and glycemic variability (CV%). These become your comparison points.

2. Start with low-dose liraglutide (0.6 mg/day subcutaneous). The meta-analytic data suggests liraglutide at 1.2 mg may be more beneficial than 0.6 mg, but titration from 0.6 mg minimizes GI side effects — nausea, which is the primary reason people discontinue ^[3]. Maintain this dose for 2 weeks minimum.

3. Titrate to 1.2 mg/day if tolerated. Based on the Mirghani and Alhowiti analysis, 1.2 mg showed the most favorable HbA1c reduction profile (SMD −0.87) ^[3]. Monitor for hypoglycemia carefully during titration — you will likely need to reduce basal and/or bolus insulin doses proactively.

4. Reduce insulin dose proactively. The Popovic et al. meta-analysis showed average reductions of 5.74 U/day in total insulin dose ^[4]. Don't wait for hypoglycemia to force the adjustment. A reasonable starting reduction is 10–15% of basal insulin at the time of GLP-1 RA initiation, with further adjustments based on CGM data.

5. Monitor at 4-week intervals. Repeat HbA1c at 12 weeks (the minimum meaningful interval for glycated hemoglobin turnover). Track weight weekly. Run CGM reports every 2 weeks to watch for emergent hypoglycemia patterns, especially overnight.

6. Reassess at 12 weeks. If HbA1c has dropped, weight is trending down, and insulin requirements have decreased without increased hypoglycemia — continue. If time-in-range hasn't improved and GI side effects persist, the evidence base doesn't strongly support pushing further.

7. Do not combine with SGLT2 inhibitors without specialist oversight. The DKA risk with SGLT2i in T1D is real and potentially serious. Layering two adjunct therapies on insulin multiplies complexity and risk.

VERDICT#

Score: 6.5/10

The evidence for GLP-1 RAs as adjunct therapy in T1D is real but modest. Two solid meta-analyses confirm statistically significant reductions in HbA1c, weight, and insulin dose without increased hypoglycemia — but we're talking about a 0.23% HbA1c improvement, and time-in-range wasn't significantly affected. That's not nothing, but it's not transformative either. The mechanistic work on triple agonists is genuinely interesting — the IUB447 data clarifying GLP-1R dominance in the Gαq–TRPM5 pathway is the kind of clean receptor pharmacology that actually moves the field forward. But it's preclinical, it's in mice, and extrapolating to human T1D protocols requires several leaps I'm not comfortable making yet. For adult-onset T1D patients with obesity who've exhausted optimization of their insulin regimen, adding liraglutide is a reasonable evidence-based option. For everyone else, I'd wait for larger, longer trials — and frankly, for a trial that actually shows time-in-range improvement.